drugset
drugset / Trial / NCT00161642

Study Evaluating CMD-193 in Advanced Malignant Solid Tumors

NCT00161642 ↗

Phase 1 Completed 54 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of CMD-193. Preliminary information about how a person's body processes CMD-193 and how CMD-193 affects tumors will also be collected.

Timeline

Start
2004-11
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject CMD-193 Monoclonal antibody — —

Indications

neoplasm